How many injectable sessions are usually needed?
How many injectable sessions are usually needed? For vulvo-vaginal injectables used alongside care for genitourinary syndrome of menopause (GSM), many plans start with 2–3 sessions spaced 4–8 weeks apart, then reassess at 3–6 months. The exact number depends on symptoms (dryness, dyspareunia, micro-tears), product (e.g., platelet-rich plasma or polynucleotides), and response. Foundations—moisturisers, suitable lubricants, and local oestrogen or DHEA when needed—remain first line. Educational only. Results vary. Not a cure.
Detailed Medical Explanation
How many injectable sessions are usually needed? For intimate-area injectables used to support comfort in genitourinary syndrome of menopause (GSM)—for example, platelet-rich plasma (PRP) or polynucleotides—most clinics plan an initial series of 2–3 sessions spaced about 4–8 weeks apart. This schedule gives tissue time to settle and lets you judge real-world changes like reduced “paper-cut” stinging at the vestibule/posterior fourchette, fewer micro-tears, and easier initial penetration (dyspareunia often eases first). A review at 3–6 months is typical to decide whether you need a top-up, to continue foundations alone, or to pivot (for instance, optimise local oestrogen placement if hydration remains poor).
Why multiple sessions? GSM is driven by low oestrogen, which thins the vaginal epithelium, raises pH and reduces protective lactobacilli. Injectables like PRP and polynucleotides do not replace this biology; they are explored as adjuncts aiming to condition tissue and improve “slip” where friction hurts most (usually the vestibule). Their effects, when they occur, are gradual and cumulative over weeks. Many people feel calmer day-to-day movement and less stinging with urine contact first; deeper comfort during intimacy follows with continued use of a compatible personal lubricant (water-based for versatility/condoms; silicone-based for long glide; oil-based feels rich but may degrade latex condoms/toys).
PRP vs polynucleotides and spacing. PRP (autologous platelet concentrate) is typically injected in small aliquots to the symptomatic entrance/vaginal wall with numbing; spacing of 4–6 weeks is common. Polynucleotides (biostimulatory DNA fragments, sometimes salmon-derived) are placed superficially to condition mucosa and support water binding; spacing of 4–8 weeks is usual. Technique and placement matter more than brand: if your pain is entrance-focused, targeted treatment of the vestibule is crucial; internal-only strategies can miss the sore spot.
Where injectables fit in a UK pathway. Step one is always non-hormonal foundations: a scheduled vaginal moisturiser (many prefer hyaluronic-acid gels) several times weekly, plus a generous, compatible lubricant for higher-friction moments. If symptoms affect quality of life, UK guidance supports adding low-dose local vaginal oestrogen (cream, tablet/pessary, or ring) or considering vaginal DHEA. Injectables are optional add-ons if you have persistent entrance-focused soreness or if hormones are unsuitable/declined. See our clinic overview of how we sequence treatment steps and a plain-English breakdown of treatment prices for planning.
Setting expectations and when to pause. Not everyone improves with injectables. If there is little change after the second session, it’s sensible to pause and re-check the diagnosis (e.g., lichen sclerosus, contact dermatitis, vestibulodynia, BV/thrush/UTI), ensure any local oestrogen is reaching the vestibule (fingertip application can help), and address pelvic floor guarding with pelvic health physiotherapy—injectables cannot relax muscles. Defer procedures if you have active infection, fever, unexplained bleeding, or recent pelvic/perineal surgery without clearance. People with bleeding disorders/anticoagulation need individual plans; those with severe fish allergy should avoid salmon-derived polynucleotides.
Trusted UK resources. For plain-English symptom advice on dryness and painful sex, see the NHS pages; UK guidance on GSM places moisturisers/lubricants first and supports local oestrogen when quality of life is impacted. The BNF provides product-level cautions for local therapies. Evidence syntheses on GSM treatments are available via the Cochrane Library and PubMed (public abstracts). Useful starting points: NHS: vaginal dryness, NICE Menopause Guideline (NG23), BNF, Cochrane Library, and PubMed.
Clinical Context
Who might suit 2 sessions vs 3? If your main issue is dryness with occasional “paper-cut” splits and you respond quickly to foundations, two sessions 4–8 weeks apart may be enough. Long-standing vestibular micro-tears, cycling-triggered friction, or mixed symptoms (dryness + dyspareunia + urine-on-skin sting) often lead to a three-session plan before reassessment at 3–6 months.
Who should delay or seek review first? Anyone with malodorous green/grey discharge, intense itch with thick white discharge, fever, visible blood in urine, new post-menopausal bleeding, or recent pelvic/perineal surgery without clearance. If deep pelvic pain dominates, consider endometriosis/adenomyosis pathways; if pelvic floor over-activity is prominent, start with pelvic health physiotherapy and graded dilator work.
Alternatives and next steps. Keep external care gentle (lukewarm water; bland emollient as a soap substitute), wear breathable underwear, and avoid fragranced products. Maintain a scheduled moisturiser and use a generous, compatible lubricant (silicone-based often gives longest glide for vestibular tenderness). If hormones are acceptable, optimise local oestrogen or consider DHEA before repeating injections; review at 6–12 weeks to titrate to the lowest effective maintenance.
Evidence-Based Approaches
Guidelines & patient resources (UK): The NHS overview of vaginal dryness gives self-care and when to seek help. The NICE Menopause Guideline (NG23) recommends offering information on vaginal moisturisers and lubricants and considering low-dose local vaginal oestrogen when GSM affects quality of life; local options can be used with or without HRT.
Comparators with stronger evidence: Cochrane reviews consistently show local vaginal oestrogens improve dryness, soreness, dyspareunia and vaginal pH versus placebo across creams, pessaries/tablets and rings, providing a benchmark for symptom relief (Cochrane Library).
Product detail & cautions: UK prescribing information and cautions for vaginal oestrogens and prasterone (DHEA) appear in the British National Formulary (BNF). These therapies directly address the low-oestrogen biology of GSM and are typically more impactful than injectables on baseline hydration.
Emerging evidence for injectables: Peer-reviewed pilot studies and case series of PRP and polynucleotides in GSM/vestibular pain (public abstracts via PubMed) suggest potential benefit but highlight heterogeneity in preparation, dosing and follow-up, so routine dosing schedules remain clinician-guided rather than guideline-mandated.
Applying the evidence: Use a stepped plan—foundations → add local therapy if needed → consider injectables as adjuncts only when guideline-led measures are insufficient or unsuitable. When injectables are chosen, plan 2–3 sessions 4–8 weeks apart with objective review at 3–6 months; optimise vestibule-targeted care and pelvic floor support to sustain gains. ® belongs to its owner.